Literature DB >> 8783399

Prognostic factors of local control after radiotherapy in T1 glottic and supraglottic carcinoma of the larynx.

J Carl1, L J Andersen, M Pedersen, O Greisen.   

Abstract

This study presents a retrospective analysis of a consecutive series of 161 patients treated with curatively intended radiotherapy for T1 supraglottic or glottic carcinoma from 1972 to 1990 at the Department of Oncology, Aalborg County Hospital, Denmark. All patients received radiotherapy given with 4-MV X-rays on lateral opposed fields. Intended dose was 60 Gy in 30 fractions. Multivariate analysis of recorded clinical parameters was applied to identify possible prognostic factors of local control. Tumor size, differentiation grade and sex were identified as significant independent prognostic parameters of local control. Five-year local control was 58% and 78% for supraglottic and glottic tumors, respectively. Applying salvage surgery the ultimate control rates were 82% and 97% for supraglottic and glottic tumors, respectively. Evaluation of treatment response 3-6 weeks following accomplishment of radiotherapy demonstrated that remaining tumor at the time of evaluation was an indicator of failure in local control.

Entities:  

Mesh:

Year:  1996        PMID: 8783399     DOI: 10.1016/0167-8140(96)01738-0

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  3 in total

1.  Radiotherapy for head and neck cancer.

Authors:  Shyh-An Yeh
Journal:  Semin Plast Surg       Date:  2010-05       Impact factor: 2.314

2.  [The postoperative T classification (pT) of primary vocal cord carcinomas and its significance for clinical classification (cT)].

Authors:  A Becker
Journal:  Strahlenther Onkol       Date:  1997-05       Impact factor: 3.621

3.  Predictors of radiotherapy outcome in patients with T2 supraglottic carcinoma.

Authors:  Tomasz Rutkowski; A Wygoda; K Składowski; B Hejduk; R Rutkowski; B Lukaszczyk-Widel; M Hutnik; B Maciejewski
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-11-25       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.